肝纤维化的发病机制及治疗新靶点

被引:66
作者
张伟
贾继东
机构
[1] 首都医科大学附属北京友谊医院肝病中心
关键词
肝硬化; 治疗; 述评;
D O I
暂无
中图分类号
R575.2 [肝硬变];
学科分类号
100201 [内科学];
摘要
近年来,肝纤维化的基础研究进展非常迅速。简单回顾了肝纤维化的细胞和分子发病机制,主要包括肌成纤维细胞的来源、免疫调节、自噬、表观调节。同时简要介绍了肝纤维化的几种治疗策略,为肝纤维化的治疗提供新的治疗靶点,分析表明祛除病因是目前最重要的抗肝纤维化治疗方法。尽管目前已经出现了针对不同靶点的抗纤维化药物,但大多数还处于早期研发阶段,尚需经过严格的临床研究才能确认其疗效。
引用
收藏
页码:409 / 412
页数:4
相关论文
共 15 条
[1]
Cellular and molecular mechanisms in the pathogenesis of liver fibrosis:An update[J] Gülsüm ?zlem Elpek; World Journal of Gastroenterology 2014,
[2]
Simtuzumab treatment of advanced liver fibrosis in HIV and HCV ‐infected adults: results of a 6‐month open‐label safety trial[J] Eric G. Meissner;Mary McLaughlin;Lindsay Matthews;Ahmed M. Gharib;Bradford J. Wood;Elliot Levy;Ralph Sinkus;Kimmo Virtaneva;Dan Sturdevant;Craig Martens;Stephen F. Porcella;Zachary D. Goodman;Bittoo Kanwar;Robert P. Myers;Mani Subramanian;Colleen Hadigan;Henry Masur;David E. Kleiner;Theo Heller;Shyam Kottilil;Joseph A. Kovacs;Caryn G. Morse Liver International 2016,
[3]
Emerging therapeutic targets for the treatment of hepatic fibrosis[J] Paolo Fagone;Katia Mangano;Antonio Pesce;Teresa Rosanna Portale;Stefano Puleo;Ferdinando Nicoletti Drug Discovery Today 2016,
[4]
Recent advancement of molecular mechanisms of liver fibrosis[J] Ekihiro Seki;David A. Brenner J Hepatobiliary Pancreat Sci 2015,
[5]
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic; non-alcoholic steatohepatitis (FLINT): a multicentre; randomised; placebo-controlled trial[J] Brent A Neuschwander-Tetri;Rohit Loomba;Arun J Sanyal;Joel E Lavine;Mark L Van Natta;Manal F Abdelmalek;Naga Chalasani;Srinivasan Dasarathy;Anna Mae Diehl;Bilal Hameed;Kris V Kowdley;Arthur McCullough;Norah Terrault;Jeanne M Clark;James Tonascia;Elizabeth M Brunt;David E Kleiner;Edward Doo The Lancet 2015,
[6]
Circulating MicroRNAs as a marker for liver injury in human immunodeficiency virus patients[J] Evrim Anadol;Robert Schierwagen;Natalia Elfimova;Katharina Tack;Carolynne Schwarze‐Zander;Hanna Eischeid;Andrea Noetel;Christoph Boesecke;Christian Jansen;Leona Dold;Jan‐Christian Wasmuth;Christian P. Strassburg;Ulrich Spengler;Jürgen Kurt Rockstroh;Margarete Odenthal;Jonel Trebicka Hepatology 2015,
[7]
Autophagy: A Multifaceted Partner in Liver Fibrosis[J] Ariane Mallat;Jasper Lodder;Fatima Teixeira-Clerc;Richard Moreau;Patrice Codogno;Sophie Lotersztajn;Pascal Colosetti BioMed Research International 2014,
[8]
q Fibrosis: A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients[J] Shuoyu Xu;Yan Wang;Dean C.S. Tai;Shi Wang;Chee Leong Cheng;Qiwen Peng;Jie Yan;Yongpeng Chen;Jian Sun;Xieer Liang;Youfu Zhu;Jagath C. Rajapakse;Roy E. Welsch;Peter T.C. So;Aileen Wee;Jinlin Hou;Hanry Yu Journal of Hepatology 2014,
[9]
Antifibrotic Effects of a Recombinant Adeno-Associated Virus Carrying Small interfering RNA Targeting TIMP-1 in Rat Liver Fibrosis[J] Min Cong;Tianhui Liu;Ping Wang;Xu Fan;Aiting Yang;Yanfeng Bai;Zhen Peng;Peng Wu;Xiaofei Tong;Jing Chen;Hai Li;Rui Cong;Shuzhen Tang;Baoen Wang;Jidong Jia;Hong You The American Journal of Pathology 2013,
[10]
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis[J] Roberta D'Ambrosio;Alessio Aghemo;Maria Grazia Rumi;Guido Ronchi;Maria Francesca Donato;Valerie Paradis;Massimo Colombo;Pierre Bedossa Hepatology 2012,